undamentalytics Newsletter

Marker Therapeutics, Inc. valuation and forecast

Explore the models for Marker Therapeutics, Inc., adjust their assumptions and compare your own valuation with the platform's.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Analyst recommendations

3 analysts, Oct 2026
Buy3100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202633
  2. Sep 202633
  3. Aug 202633

Counts of recommendations published by analysts covering Marker Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Price history

Loading chart…

Third-party market data · may be delayed

MRKR valuation questions

How does Fundamentalytics value Marker Therapeutics, Inc.?
We use the models that fit Marker Therapeutics, Inc.'s business and available financial data: price-to-sales vs peers. Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.

Data: SEC EDGAR filings, retrieved November 1, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Marker Therapeutics, Inc.

Compare with peers